Buy Azafen pills 25 mg, 50 pcs
  • Buy Azafen pills 25 mg, 50 pcs

Azafen® [Pipofezine]

1857 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Tricyclic antidepressant from the group of indiscriminate inhibitors of neuronal monoamine uptake.
The mechanism of antidepressant action is associated with the indiscriminate inhibition of the reverse neuronal capture of serotonin and norepinephrine, which leads to an increase in their concentrations in the central nervous system. Thymoleptic effect of the drug combined with sedative activity and anxiolytic effect.
Practically does not possess m-anticholinergic activity, does not affect the activity of monoamine oxidase (MAO). It has no cardiotoxic effect.
Quickly and completely absorbed in the gastrointestinal tract. Bioavailability is about 80%. After oral administration of a single dose of 25 mg Azafen, the maximum concentration is 24.5 ng / ml and is determined after 1-2 hours. Communication with plasma proteins - 90%.
Metabolized in the liver to form inactive metabolites. An in vitro study has shown that pipofesin is not a substrate of CYP2C9, CYP2C19, CYP2D6, and CYP3A4 isoenzymes, but is primarily metabolized by the CYP1A2 isoenzyme.
The drug is rapidly removed from the bloodstream, the half-life is 4.3 hours. Excreted mainly by the kidneys.


Depressive episodes of mild and moderate severity (including chronic somatic diseases).


Active substance
Pipofesin dihydrochloride monohydrate 25 mg;
Potato starch, colloidal silicon dioxide (aerosil), microcrystalline cellulose, lactose monohydrate, povidone (low-molecular medical polyvinylpyrrolidone), magnesium stearate.

No customer reviews for the moment.

Write your review

Write your review

Azafen® [Pipofezine]

Dosage and Administration

Intravenously. The daily dose is 30–160 mg / kg (3–12 g / day), the frequency of administration is 2–4 times daily. Parenteral administration of piracetam is prescribed when it is impossible to use oral forms of the drug, for example, when difficulty in swallowing, or when the patient is in a coma.

The lucetam solution is compatible with the following infusion solutions:

- Glucose 5, 10, 20%;

- Fructose 5, 10, 20%;

- Levulose 5%;

- Sodium chloride 0.9%;

- Dextran 40 10% in 0.9% sodium chloride solution;

- Dextran 100 6% in 0.9% sodium chloride solution;

- Ringer's solution;

- Mannitol-Dextran;

- Hydroxyethyl starch 6%.

Infusion solutions with the addition of piracetam are stable for at least 24 hours.

Adults.Symptomatic treatment of psychoorganic syndrome: for symptomatic treatment of chronic psychoorganic syndrome, depending on the severity of symptoms, 2.4-4.8 g / day is prescribed, distributing by 2-3 administrations.

Treatment of vertigo and related balance disorders: 2.4–4.8 g / day, distributing for 2–3 injections.

Cortical myoclonus: treatment starts from 7.2 g / day, every 3-4 days, the dose is increased by 4.8 g / day until the maximum dose is reached - 24 g / day. In the future, switch to oral form lucetam. Treatment continues throughout the duration of the disease. To prevent deterioration of the patients can not abruptly stop using the drug. It is necessary to gradually lower the dose of the drug. In the absence of effect or in the presence of a minor therapeutic effect, treatment is stopped.

Stopping (parenteral) sickle cell vasoclastic crisis: the drug is used at a dose of 300 mg / kg, divided into 4 doses.

Kids and teens

In the complex treatment of dyslexia in children aged 8 years: the daily dose is 3.2 g, divided into 2 administrations.

Relief of sickle-cell vazoozlyuzionnogo crisis in children over 3 years of age: 300 mg / kg, divided into 4 doses.

Dosing for patients with impaired renal function: Since Piracetam is excreted by the kidneys, care should be taken when treating patients with renal insufficiency in accordance with the dosage regimen given.

The calculation of the dose should be based on the assessment of creatinine clearance in a patient and a table of recommendations for treating patients, depending on the severity of renal failure, see above.

Dosing for elderly patients. For elderly patients, the dose is corrected in the presence of renal failure, and with prolonged therapy, monitoring of renal function is necessary.

Dosing for patients with impaired liver function. Patients with impaired liver function do not need dose adjustment.

Adverse reactions

Nervous system disorders: hyperkinesis, irritability, drowsiness, depression, asthenia: these symptoms occur more often in elderly patients receiving doses exceeding 2.4 g / day, in most cases it is possible to regress these symptoms by reducing the dose of the drug. Headache, dizziness, insomnia, mental agitation, anxiety, imbalance, tremor, ataxia, exacerbation of the course of epilepsy, anxiety, hallucinations, confusion, increased libido.

Blood and lymph disorders: bleeding

Immune system disorders: hypersensitivity, including anaphylaxis

Disturbances from an organ of hearing and a labyrinth: vertigo

Violations of the cardiovascular system: decrease or increase in blood pressure.

Disorders of the digestive system: nausea, vomiting, diarrhea, abdominal pain, epigastric pain.

Metabolic and nutritional disorders: weight gain.

Violations of the skin: dermatitis, pruritus, urticaria.

Allergic reactions: angioedema.

General disorders and disorders at the site of administration: pain at the injection site, thrombophlebitis, hyperthermia.

  • Hemorrhagic stroke.
  • End-stage renal failure (with creatinine clearance less than 20 ml / min).
  • Children's age up to 1 year.
  • Pregnancy.
  • Lactation.
  • Hypersensitivity to piracetam or a derivative of pyrrolidone, as well as other components of the drug.

Drug interactions

If applied simultaneously with an extract of the thyroid gland, irritability, disorientation and sleep disturbance are possible.

No interactions with clonazepam, phenytoin, phenobarbital, sodium valproate.

High-dose piracetam (9.6 g / day) increases the effectiveness of acenocoumarol in patients with venous thrombosis (there was a more pronounced decrease in the level of platelet aggregation, fibrinogen levels, von Willebrand factors, blood and plasma viscosity).

The possibility of changing the pharmacodynamics of piracetam under the influence of other drugs is low, because 90% of the drug is excreted unchanged in the urine.

In vitro, piracetam does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 4A9 / 11 isoenzymes at 142, 426, and 1422 mcg / ml. At a concentration of piracetam of 1422 mcg / ml, slight inhibition of CYP2A6 (21%) and 3A4 / 5 (11%) was observed. However, the level Ki of these two isoenzymes is sufficient when exceeding 1422 μg / ml. Therefore, metabolic interaction with other drugs is unlikely.

Reception of piracetam in a dose of 20 mg / day did not change the peak and the curve of the concentration level of antiepileptic drugs in serum (carbamazepine, phenytoin, phenobarbital, valproate) in epilepsy patients receiving the drug in a constant dose.

Co-administration with ethanol did not affect the level of serum pyracetam concentration, the concentration of ethanol in blood serum did not change when taking 1.6 g pyracetam.

Pregnancy and Lactation

Studies on animals did not reveal a damaging effect on the embryo and the development of offspring, including in the postnatal period, as well as the course of pregnancy and childbirth. Studies in pregnant women have not been conducted. Piracetam penetrates the placental barrier and into breast milk. The concentration of the drug in newborns reaches 70-90% of its concentration in the blood of the mother. Except in special circumstances, lucetam should not be administered during pregnancy. You should refrain from breastfeeding when prescribing a woman Lucetam.

Special instructions

In connection with the effect of piracetam on platelet aggregation, the drug should be prescribed with caution to patients with impaired hemostasis, during major surgical operations or patients with symptoms of severe bleeding.

When treating cortical myoclonus, abrupt interruption of treatment should be avoided, which may cause the resumption of seizures.

Gets through the filtering membranes of hemodialysis machines.

With long-term therapy in elderly patients, regular monitoring of renal function indicators is recommended, and if necessary, dose adjustment is carried out depending on the results of the QC study.

Taking into account possible side effects, the patient should be careful when driving a car and working with mechanisms.

  • Brand name: Azafen
  • Active ingredient: Pipofezine
  • Dosage form: 25 mg pills.
    10 or 14 pills in a blister pack.
    On 100, 200, 250, 300 pills in polymeric cans, corked by covers.
    Polymer can or 3, 4, 5 blister packs of 10 pills or 1, 2, 3, 4 blister packs of 14 pills together with instructions for use are placed in a pack of cardboard.
  • Manufacturer: Makiz-Pharma
  • Country of Origin: Russia

8 other products in the same category: